Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Atrial Fibrillation, Atrial Flutter
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- Heart rate >125
- Systolic BP>110
- Atrial Fibrillation/Flutter confirmed on ECG.
- Meets observation unit requirements (performs certain ADL's (acts of daily living)
- Age>18.
Exclusion Criteria:
- Wolf-Parkinson-White syndrome
- ST Elevation Myocardial Infarction
- Pregnant
- Clinical diagnosis of Sepsis,
- Decompensated HF
- allergy to Diltiazem
- provider discretion
- clinical need for cardioversion
Sites / Locations
- Matthew Hysell
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Diltiazem with oral and intravenous treatment
traditional atrial fibrillation with rapid ventricular response
Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg. 15 minutes following Diltiazem Infusion administer oral Diltiazem 60mg IR Tablet, do not give if BP<100
these patients will receive traditional treatments at provider discretion. To be included in teh study their initial heart rate must also be over 125, and they must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.